Actualisées dans « La surveillance de la santé publique dans le contexte de la COVID-19 », publié le 16 décembre 2020
World J Meta-Anal. Aug 26, 2017; 5(4): 103-123
Published online Aug 26, 2017. doi: 10.13105/wjma.v5.i4.103
Lancet Glob Health 2018 Published Online September 12, 2018 http://dx.doi.org/10.1016/S2214-109X(18)30409-1
Pharmaceuticals 2024, 17(6), 691; https://doi.org/10.3390/ph17060691
This document summarizes the findings of the STEPS survey in Ukraine and compares them with the results of STEPS surveys carried out in other countries in the WHO European Region, as well as with selected other surveys in Ukraine. The survey is designed to be repeated approximately every five years ...in each country to allow assessment of trends.
The study revealed very high prevalence of NCDs and their behavioural and biological risk factors in Ukraine. Data on behavioural risk factors include tobacco and alcohol use, diet, and physical activity. Data on biological risk factors include overweight and obesity, blood pressure, blood glucose, and blood lipid levels.
more
Introduction
Chapitre A.4
Edition en français Traduction : Eleanor O’Boyle
Sous la direction de : Priscille Gérardin
Avec le soutien de la SFPEADA
Supplement Article
J Acquir Immune Defic Syndr Volume 75, Supplement 2, June 1, 2017 www.jaids.com
Analysis of fake news disseminated during the COVID-19 pandemic in Brazil
Country profile: Democratic Republic of Congo
Journal of Computational Biophysics and ChemistryVol. 22, No. 01, pp. 31-41 (2023)
Lancet Global Health 2017 Published Online February 22, 2017 http://dx.doi.org/10.1016/S2214-109X(17)30078-5
Global COVID-19 Clinical Platform: Case Record Form for suspected cases of Multisystem inflammatory syndrome (MIS) in children and adolescents temporally related to COVID-19
Psychiatry and Pediatrics
Chapter I.4
PLoS Med. 2009 Oct;6(10):e1000159. doi: 10.1371/journal.pmed.1000159. Epub 2009 Oct 6.
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.